Estriol supports estrogen-sensitive vaginal and vulval tissues by improving moisture, elasticity, and mucosal resilience. Estriol is intended for adults with menopausal urogenital symptoms such as…
Estriol supports estrogen-sensitive vaginal and vulval tissues by improving moisture, elasticity, and mucosal resilience. Estriol is intended for adults with menopausal urogenital symptoms such as dryness and tissue thinning.
The cream contains estriol 0.01% w/w and is supplied in an 80 g tube with an applicator.
Estriol is one of the three main naturally occurring oestrogens, alongside estradiol and estrone.
Medsafe and the EMA describe local oestrogen therapy as an option for menopausal vulvovaginal symptoms, with treatment choice depending on symptoms, medical history, and the need for systemic hormone therapy [1].
The amount of Estriol is decided individually, taking age, other medicines, and health conditions into account. The prescribed amount may differ between an initial treatment period and maintenance use.
Use involves the following practical steps:
The applicator should be inserted gently. Pain, resistance, or unexpected bleeding during insertion needs medical review rather than forceful application.
Treatment duration depends on the severity of symptoms and the response. Once symptoms improve, the prescriber may reduce the frequency to the lowest regimen that maintains relief. Do not increase the amount because symptoms have not improved after one or two applications; local tissue recovery takes time.
Estriol Cream is a topical oestrogen formulation for vaginal use. The cream base helps distribute estriol across vaginal mucosa and may also be used around the vulval tissues when this forms part of the prescribed treatment plan.
The applicator is useful when the treatment is intended for internal vaginal application. A cream may feel different from a pessary or gel: some residue can remain after application, and a small amount may appear later as the base leaves the vagina.
Estriol Cream has these product characteristics:
Local estriol treatment addresses tissues affected by low oestrogen. Systemic hormone therapy delivers oestrogen through the bloodstream and is selected when symptoms extend beyond the vagina and vulva, such as troublesome vasomotor symptoms.
Low-dose local therapy can still lead to some absorption. The risk profile is lower than with many systemic regimens, but it is not zero. A history of hormone-sensitive cancer, unexplained vaginal bleeding, thrombosis, or liver disease needs specific medical assessment before treatment.
Estriol supports the maturation of vaginal epithelial cells and helps restore moisture and tissue flexibility. Local vaginal administration aims to concentrate treatment in the urogenital tissues rather than expose the whole body to the higher hormone levels associated with oral or transdermal therapy.
Menopause can reduce oestrogen stimulation in the vagina, vulva, urethra, and bladder outlet. The vaginal lining may become thinner and less elastic. Natural lubrication can fall, and the vaginal environment may become less acidic, allowing changes in the normal bacterial balance.
Treatment may reduce:
Vaginal atrophy is now often described within the broader term genitourinary syndrome of menopause. The term includes changes affecting the vagina, vulva, urethra, and lower urinary tract. Local oestrogen can improve tissue condition, but it is not an antibiotic and should not be used as the sole treatment for an established urinary tract infection.
A person with fever, flank pain, visible blood in the urine, vomiting, or rapidly worsening urinary symptoms needs assessment for infection or another urinary condition. Estriol may help reduce recurrent urogenital symptoms in selected postmenopausal patients, but it does not replace urine testing or antibacterial treatment when those are clinically indicated.
The benefit develops through repeated local exposure rather than through an immediate analgesic effect. Dryness and burning may improve before tissue fragility or recurrent urinary symptoms settle.
Several practical errors can reduce benefit or create avoidable irritation:
The applicator should be cleaned according to the product’s intended instructions, kept for the same user, and replaced if damaged. A damaged applicator can cause discomfort and make the delivered amount unreliable.
New pelvic pain, offensive discharge, fever, or bleeding needs investigation rather than an increase in Estriol.
Estriol may need special discussion with patients taking:
The WHO menopause guidance published in 2022 supports individual assessment of hormonal treatment according to symptoms, risks, and patient preference [3].
Estriol is NOT for you if unexplained bleeding, suspected hormone-sensitive cancer, or a history of clotting disease has not been medically assessed:
A prior blood clot does not automatically produce the same treatment decision for every patient, but it requires a specific risk assessment. The same applies to migraine with neurological symptoms, severe hypertension, gallbladder disease, systemic lupus, and a strong family history of hormone-sensitive cancer.
Local Estriol may cause discomfort or irritation after application. Possible effects described for local vaginal treatment include:
Persistent burning, worsening discomfort, or unexpected vaginal bleeding requires medical assessment. Treatment should be reviewed periodically, and persistent or recurrent bleeding requires investigation, even when the oestrogen dose is local [2].
The main alternatives are other local oestrogen preparations, vaginal moisturisers, lubricants, and vaginal medicines containing different active substances. Selection depends on the dominant symptom, comfort with the application method, medical history, and whether systemic menopausal symptoms also require treatment. Potential advantages of estriol include targeted local delivery, relief of dryness, and improved tissue comfort. A drawback is that improvement takes time and local reactions or cream residue can occur. Systemic menopausal symptoms may need a separate treatment plan.
| Treatment category | Active approach and route | Typical role |
|---|---|---|
| Estriol Cream | Estriol applied vaginally with an applicator | Vaginal dryness, tissue thinning, and related urogenital symptoms |
| Local estradiol | Estradiol delivered vaginally by a preparation such as a tablet, ring, or cream | Similar tissue targets with a different oestrogen molecule and dosing pattern |
| Non-hormonal moisturiser or lubricant | Water-based, silicone-based, or moisturising ingredients applied locally | Dryness or friction when oestrogen is unsuitable or not wanted |
Vaginal moisturisers can be used regularly to improve hydration, while lubricants are usually used around sexual activity. They do not stimulate oestrogen receptors and therefore do not reverse all tissue changes caused by oestrogen deficiency.
A local estradiol product may be chosen when a patient prefers its formulation or when the clinician has more experience with that dosage form. Estriol may be preferred when a lower-potency local oestrogen approach is appropriate. These treatments should not be swapped by comparing cream volume alone.
In clinical practice, doctors usually assess three things before prescribing local estriol: the symptom pattern, the appearance or history of vaginal bleeding, and the patient’s hormone-related medical risks.
A typical medical conversation also distinguishes vaginal dryness from infection, dermatitis, pelvic-floor pain, and vulval skin disease. These conditions can overlap. Estriol will not correct every cause of burning or painful intercourse.
Physicians often explain that improvement is gradual. Moisture may change first, while tissue elasticity and urinary comfort can take longer. The maintenance plan may be reduced after symptoms settle, but the treatment should not be intensified without review. Treatment response varies between patients. Dryness may improve before urinary symptoms. Some people notice residue after application. Others experience mild irritation that settles with time. Persistent bleeding or pain requires clinical review.
The 2022 North American Menopause Society position statement supports vaginal oestrogen and other local options for genitourinary symptoms when appropriate, with treatment selected according to the individual clinical situation [4].
Estriol and estradiol are both oestrogens, but estradiol has stronger receptor activity and is the dominant reproductive-age oestrogen. Estriol is less potent and is commonly used as a local option for vulvovaginal symptoms. The 2022 North American Menopause Society statement describes both local oestrogen approaches as treatment options selected according to symptoms and clinical risk .
Routine vaginal use of Estriol does not usually require a special sun-avoidance schedule because the cream is applied to internal mucosal tissue rather than exposed skin. Sun protection remains sensible for normal outdoor exposure, especially if a small amount is used externally on irritated vulval skin. Medsafe’s 2023 Consumer Medicine Information for estriol supports stopping and seeking review when a new local reaction becomes severe or persistent.
The amount is decided individually, taking age, other medicines, and health conditions into account. Apply the prescribed amount vaginally with the supplied applicator, wash your hands before and after use, and do not cover the area with an airtight dressing. The 2018 EMA Summary of Product Characteristics (SmPC) for estriol supports using the lowest amount that controls symptoms after the initial treatment plan has been completed .
Discuss unexplained vaginal bleeding, breast or endometrial cancer, previous blood clots, stroke or heart disease, liver disease, migraines with neurological symptoms, pregnancy, and allergies. Tell the clinician about tamoxifen, aromatase inhibitors, anticoagulants, and other oestrogen products. NICE menopause guidance updated in 2024 recommends reviewing the person’s symptoms, medical history, and treatment risks before hormonal therapy is selected.
Regular movement, pelvic-floor care, adequate hydration, and avoiding perfumed vaginal products can support comfort, but they do not replace local treatment when tissue thinning is the main cause. Lubricant use during sexual activity can reduce friction while the tissue recovers. The WHO 2022 menopause guidance also supports lifestyle measures as part of symptom care, while recognising that lifestyle measures do not directly restore oestrogen-sensitive tissue.
Extra care is needed when Estriol is combined with breast-cancer endocrine medicines, especially aromatase inhibitors or tamoxifen, and when another oestrogen product is being used. Anticoagulants and supplements promoted for menopause should also be disclosed because their effects may complicate bleeding assessment. The 2018 EMA Summary of Product Characteristics (SmPC) for estriol advises reviewing concomitant medicines and hormone-related conditions before continuing treatment.
Estriol is not expected to impair driving, concentration, or routine work with machinery when used locally as prescribed. Dizziness, headache, visual symptoms, or a severe allergic reaction would make driving unsafe until the symptom has been assessed. Medsafe’s 2023 Consumer Medicine Information for estriol treats new severe neurological or allergic symptoms as reasons to stop the activity and seek medical attention.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Based on 4 reviews
The dryness had been affecting exercise and intimacy. The cream felt a little messy at first, but the burning settled after the first week and intercourse became more comfortable.
Taupō Several weeks 30 Oct 2026I found the applicator easier than guessing the amount. I noticed extra discharge for a few days, which was inconvenient, and I contacted the clinic when the irritation continued.
Rotorua An initial course 4 Nov 2026The improvement was gradual rather than sudden. By the third or fourth week the tight, dry feeling was less noticeable, although I still needed a lubricant during sex.
Levin Three or four weeks 9 Oct 2026The cream helped with soreness and urinary discomfort. I was worried about the hormone content, so the review of my past breast and clotting history was useful before continuing.
Tauranga 15 Oct 2026
